{
    "clinical_study": {
        "@rank": "132733", 
        "acronym": "CHOLESS", 
        "arm_group": [
            {
                "arm_group_label": "Ezetimibe", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive for 6 months ezetimibe (10 mg/day)"
            }, 
            {
                "arm_group_label": "Nutraceuticals", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive for 6 months a commercially available nutraceutical combined pill (1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "Treatment with statins has a class I indication after percutaneous coronary intervention\n      (PCI), but is often discontinued by patients due to side effects.\n\n      Pharmacologic alternatives shown to be useful after PCI include ezetimibe and nutraceuticals\n      (i.e. compounds derived from foods with cholesterol lowering actions).\n\n      It remains unknown, however, which of these two therapeutic approaches is more effective\n      after PCI.\n\n      The primary objective of this study is to compare the efficacy and tolerability of ezetimibe\n      vs. a nutraceutical-based protocol in statin-intolerant patients treated with percutaneous\n      coronary intervention."
        }, 
        "brief_title": "Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "Background\n\n      Treatment with statins has a class I indication after percutaneous coronary intervention\n      (PCI), but is often discontinued by patients due to side effects.\n\n      Pharmacologic alternatives shown to be useful after PCI include ezetimibe and nutraceuticals\n      (i.e. compounds derived from foods with cholesterol lowering actions).\n\n      It remains unknown, however, which of these two therapeutic approaches is more effective\n      after PCI.\n\n      Purpose\n\n      The primary objective of this study is to compare the efficacy and tolerability of ezetimibe\n      vs. a nutraceutical-based protocol in statin-intolerant patients treated with percutaneous\n      coronary intervention.\n\n      Study Population\n\n      Patients with coronary artery disease in stable conditions treated with percutaneous\n      coronary intervention who have withdrawn statin treatment due to side effects\n\n      Randomization\n\n      Patients will be randomized to receive for 6 months either ezetimibe (10 mg/day) or a\n      commercially available nutraceutical combined pill (1 capsule/day containing monacolin K 10\n      mg, policosanol 10 mg, and phytosterols 300 mg)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Angiographically-proven coronary artery disease\n\n          -  Recent (<12 months) percutaneous coronary intervention\n\n          -  Class I indication to receive statin treatment\n\n          -  Previous (<12 months) withdrawn of a statin due to side effects\n\n          -  Unwilling to receive treatment with an alternative statin\n\n          -  Able to understand and willing to sign the informed consent form\n\n        Exclusion Criteria:\n\n        \u2022 Women of child bearing potential patients must demonstrate a negative pregnancy test\n        performed within 24 hours before CT"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807078", 
            "org_study_id": "222-D-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ezetimibe", 
                "description": "10 mg p.d. of ezetimibe", 
                "intervention_name": "Ezetimibe", 
                "intervention_type": "Drug", 
                "other_name": "Zetia"
            }, 
            {
                "arm_group_label": "Nutraceuticals", 
                "description": "1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg", 
                "intervention_name": "Nutraceuticals", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Choless", 
                    "Fixlipid"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ezetimibe"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Coronary artery disease", 
        "lastchanged_date": "March 6, 2013", 
        "location": {
            "contact": {
                "email": "f.pelliccia@mclink.it", 
                "last_name": "Francesco Pelliccia, MD", 
                "phone": "+39064997", 
                "phone_ext": "123"
            }, 
            "contact_backup": {
                "email": "md4151@mclink.it", 
                "last_name": "Giuseppe Marazzi, MD", 
                "phone": "+39064997", 
                "phone_ext": "123"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "state": "Lazio", 
                    "zip": "00161"
                }, 
                "name": "Sapienza University"
            }, 
            "investigator": {
                "last_name": "Francesco Pelliccia, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Comparison of the CHOlesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant patientS - The CHOLESS Trial", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reasons for treatment discontinuation", 
            "measure": "Reasons for treatment discontinuation", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807078"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Roma La Sapienza", 
            "investigator_full_name": "Francesco Pelliccia", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Effects on cholesterol plasmatic levels", 
            "measure": "Effects on lipid profile", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "University of Roma La Sapienza", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Roma La Sapienza", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}